Cargando…

Impact of tocilizumab administration on mortality in severe COVID-19

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a significant burden on hospitals and healthcare providers. The immune response to this disease is thought to lead to an aberrant inflammatory response or cytokine storm, which contributes to the severity of illness. There i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Andrew, Diawara, Oumou, Nahass, Ronald G., Brunetti, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645706/ https://www.ncbi.nlm.nih.gov/pubmed/33154452 http://dx.doi.org/10.1038/s41598-020-76187-y

Ejemplares similares

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
por: Brunetti, Luigi, et al.
Publicado: (2020)

Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis
por: Hong, Thomas S., et al.
Publicado: (2020)

512. Does Time From COVID-19 Symptom Onset to Administration of Anti-spike Protein Monoclonal Antibody Predict Response?
por: SanFilippo, Savanna, et al.
Publicado: (2021)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
por: Pagkratis, Konstantinos, et al.
Publicado: (2022)

Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
por: Deana, Cristian, et al.
Publicado: (2021)

Tocilizumab and COVID-19: Timing of administration assessment
por: Richier, Q., et al.
Publicado: (2022)

Tocilizumab and COVID-19: Timing of Administration and Efficacy
por: Abidi, Emna, et al.
Publicado: (2022)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin–Preclinical and Clinical Evidence
por: Brunetti, Luigi, et al.
Publicado: (2023)

Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis
por: San Filippo, Savanna, et al.
Publicado: (2022)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Lack of tocilizumab effect on mortality in COVID19 patients
por: Holt, Gregory E., et al.
Publicado: (2020)

Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
por: Rutgers, Abraham, et al.
Publicado: (2022)

Tocilizumab is recommended for the treatment of severe COVID-19
por: Zhou, Yonggang, et al.
Publicado: (2020)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
por: Capra, Ruggero, et al.
Publicado: (2020)

Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
por: Wang, Yong, et al.
Publicado: (2022)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
por: Gavriilidis, Efstratios, et al.
Publicado: (2022)

Bowel ulceration following tocilizumab administration in a COVID-19 patient
por: Bruce-Hickman, Damian, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Effective treatment of severe COVID-19 patients with tocilizumab
por: Xu, Xiaoling, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19: A promise fulfilled
por: Levi, Marcel
Publicado: (2022)

Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
por: Hong, Jin Yeong, et al.
Publicado: (2022)

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
por: Rubio-Rivas, Manuel, et al.
Publicado: (2020)

Tocilizumab in patients with severe COVID-19: a retrospective cohort study
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
por: Li, Pan, et al.
Publicado: (2021)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
por: Kaye, Avi Gurion, et al.
Publicado: (2020)

The Impact of Tocilizumab on Radiological Changes Assessed by Quantitative Chest CT in Severe COVID-19 Patients
por: Anghel, Ana-Maria-Jennifer, et al.
Publicado: (2022)

Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review
por: Ould Ouali, Cid, et al.
Publicado: (2022)

Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
por: Klopfenstein, Timothée, et al.
Publicado: (2020)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a1ej8ttbt8i244j4vus3fujsdm